CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hainan Poly Pharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hainan Poly Pharm Co Ltd
Guilinyang Economic Development Zone
Meilan District
Phone: +86 89866661090p:+86 89866661090 HAIKOU, HAN  571127  China Fax: +86 89865710298f:+86 89865710298
This company is no longer actively traded on any major stock exchange.
Business Summary
Hainan Poly Pharm Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceutical products. The Company's main products are prescription drugs, covering anti-allergic drugs, antipyretic analgesic drugs, antibiotics, digestive drugs, cardiovascular and cerebrovascular drugs, contrast agents, emergency rescue drugs and other fields. The Company's products mainly include levetiracetam concentrated solution for injection, bivalirudin for injection, azithromycin for injection, voriconazole for injection, ganciclovir for injection, pantoprazole sodium for injection, vancomycin hydrochloride for injection, sodium nitroprusside injection, eptifibatide injection, terlipressin injection, levofloxacin tablets, desloratadine tablets, dicyclomine injection, desloratadine dry suspension, azithromycin dry suspension, fluconazole dry suspension, voriconazole dry suspension, oseltamivir phosphate capsules, lacosamide injection and other products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager MinhuaFan 62 10/30/2012 10/30/2012
Chief Financial Officer, Deputy General Manager, Director TongningLuo 47 11/27/2018 10/30/2012
Deputy General Manager, Secretary of the Board, Director MaoZhou 53 6/1/2015 1/1/2009
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,565 (As of 12/31/2023)
Outstanding Shares: 561,309,351 (As of 3/31/2025)
Shareholders: 40,004
Stock Exchange: SHE
Fax Number: +86 89865710298


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 23, 2025